FDA Decisions Expected: October 2025 Prime Therapeutics Portal A new FDA advisory panel meeting, influenced by RFK Jr.'s push for broader access, will weigh the potential benefits and risks of widely promoted peptides. Click the link in bio to read Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law New: An FDA decision to place 19 peptides on the unsafe list was supported by numerous documented safety concerns, former officials said. Even though demand for peptide therapies has exploded since then, When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions